Výsledky vyhledávání - "PI3K/mTOR Inhibitor LY3023414"

Abstract 3508: Combination of the Chk1 inhibitor (prexasertib) with a PI3K/mTOR inhibitor (LY3023414) induces synergistic anti-tumor activity in triple negative breast cancer (TNBC) models

Autor: Greg Donoho, Jennifer R. Stephens, Mark A. Castanares, Christoph Reinhard, Karsten Boehnke, Aimee Lin, Wenjuan Wu, Jack A. Dempsey, Andrew Capen, Philip W. Iversen

Publikováno v: Cancer Research. 79:3508-3508

TNBC, the most aggressive subtype of breast cancer, is characterized by high level of genomic instability, defects in DNA damage response (DDR) and increased replication stress (RS). The current treatment options for TNBC are limited and new approach

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3d12c438c368f4bb866cf5b01bd668a4
https://doi.org/10.1158/1538-7445.am2019-3508

Zobrazit plný text záznamu

Abstract 1761: Inhibition of PI3K/AKT/mTOR signaling by a dual PI3K/mTOR inhibitor (LY3023414) potentiates the antitumor efficacy of the Chk1 inhibitor prexasertib (LY2606368) in models of human high-grade serous ovarian cancer (HGSOC)

Autor: Ann M. McNulty, Philip W. Iversen, Christoph Reinhard, Wenjuan Wu, Greg Donoho, Louis Stancato, Jack A. Dempsey, Jennifer R. Stephens, Ricardo Martinez, Aimee Lin

Publikováno v: Cancer Research. 79:1761-1761

HGSOC (characterized by defects in DNA damage repair and high levels of genomic instability and DNA replication stress) is the most lethal gynecological malignancy in the United States. The current treatment options for HGSOC are limited and new appr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f4fd2f66571cb5612c95803f8d3a0d60
https://doi.org/10.1158/1538-7445.am2019-1761

Zobrazit plný text záznamu

Abstract 5467: Efficacy of the ERK inhibitor LY3214996 and the PI3K/mTOR inhibitor LY3023414 in patient-derived RAS-mutant NSCLC models

Autor: Amanda J. Redig, Man Xu, Atsuko Ogino, Ramon V. Tiu, Patrick Brueck, Emily S. Chambers, Hong L. Tiv, Prafulla C. Gokhale, Jihyun Choi, Paul Kirschmeier, Margaret K. Wilkens, Greg Donoho, Pasi A. Jänne, Jiaqi Li, Shripad V. Bhagwat, Jens Köhler

Publikováno v: Cancer Research. 78:5467-5467

Introduction: RAS mutations are present in 30% of non-small cell lung cancer (NSCLC) and, despite activated MAPK signaling, MEK inhibitors have disappointed in clinical trials. MAPK pathway reactivation and activation of anti-apoptotic signaling via

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::222b249ee51c6ea45a0ba5dd34efece7
https://doi.org/10.1158/1538-7445.am2018-5467

Zobrazit plný text záznamu

Abstract CT020: Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in treatment of patients with advanced mesothelioma

Autor: David M. Hyman, Suhyun Kang, Anna M. Varghese, Anindya Chatterjee, Anna M. Szpurka, Patrick Brueck, Volker Wacheck, Axel-Rainer Hanauske, Marjorie G. Zauderer, Todd M. Bauer, Johanna C. Bendell, Silvia Novello, Evan W. Alley

Publikováno v: Cancer Research. 78:CT020-CT020

Background: The phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway is aberrantly activated in malignant mesothelioma. LY3023414 (LY) is a potent oral ATP- competitive inhibitor that selectively and potently inhibits cla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d04736eaf9af83192319a0628ce30ba8
https://doi.org/10.1158/1538-7445.am2018-ct020

Zobrazit plný text záznamu

Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models

Autor: Tod Smeal, Gerald Hall, Gregory P. Donoho, Thompson N. Doman, Philip W. Iversen, Manisha Brahmachary, Yung-mae M. Yao, Michael Kalos, Jason Manro, Xueqian Gong, Xuemei Guo, Sean Buchanan, Ruslan D. Novosiadly, Maxine Melchior

Publikováno v: Molecular Cancer Therapeutics. 17:B108-B108

Necitumumab (Nmab) in combination with chemotherapy has demonstrated overall survival benefit in patients with advanced or metastatic squamous non-small cell lung cancer (SqNSCLC). The PI3K/ mTOR pathway shows aberrant activity in multiple tumor type

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be095b714e497db0f011df3f884d158e
https://doi.org/10.1158/1535-7163.targ-17-b108

Zobrazit plný text záznamu

Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in combination with fulvestrant in treatment refractory advanced breast cancer patients

Autor: Kathleen N. Moore, Anna M. Varghese, Erika Hamilton, Aaron Fink, Xuejing Aimee Wang, Sophie Callies, Komal Jhaveri, Johanna C. Bendell, David M. Hyman, Volker Wacheck

Publikováno v: Journal of Clinical Oncology. 35:1064-1064

1064 Background: Thephosphatidylinositol 3-kinase (PI3K) /mammalian target of rapamycin (mTOR) pathway is frequently activated in breast cancer. LY3023414 (LY) is an oral ATP- competitive inhibitor that selectively and potently inhibits class I PI3K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8deff63cfedf0abda28425b323a510d6
https://doi.org/10.1200/jco.2017.35.15_suppl.1064

Zobrazit plný text záznamu

A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer

Autor: Sophie Callies, David M. Hyman, Shubham Pant, Ji Lin, Kathleen N. Moore, Johanna C. Bendell, Volker Wacheck, Todd M. Bauer, Anna M. Varghese

Publikováno v: Journal of Clinical Oncology. 33:11075-11075

11075 Background: The phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway is dysregulated in many malignant diseases. LY3023414 (LY) is an oral ATP competitive inhibit...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5be07decbb183f4b593c2d87f1da36f6
https://doi.org/10.1200/jco.2015.33.15_suppl.11075

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání